TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07606833: A Multicenter, Randomized, Double Blind, Double-simulated, Parallel Control of Positive Drug Phase III Clinical Study Evaluating the Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets Containing Bismuth in Q

Sponsor: Xuanzhu Biopharmaceutical Co., Ltd. · Phase: PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 556 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$13,359,360

Rescue Site Savings

+$8,808,828

Unlock Full NCT07606833 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07606833 Rescue Dossier →